SCHEMBL24987982

SCHEMBL24987982

O=C(O)C1(c2nc(-c3ccc(Cl)cc3)no2)CCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.48
▸ NOTUM Q6P988 2/20 0.44
▸ HSD11B1 P28845 1/20 0.44
▸ HSD11B2 P80365 1/20 0.44
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ CASP3 P42574 2/20 0.43
▸ SENP8 Q96LD8 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ DPP4 P27487 1/20 0.41
▸ DPP7 Q9UHL4 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ NR1H4 Q96RI1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24989004 0.97 TSHR (0.48) TSHRNOTUMHSD11B1HSD11B2NPC1
SCHEMBL25914367 0.94 TSHR (0.50) TSHRNOTUMHSD11B1HSD11B2NPC1
SCHEMBL24987960 0.90 MAP4K4 (0.47) TSHRNOTUMHSD11B1HSD11B2NPC1
SCHEMBL24988126 0.88 MAPT (0.46) TSHRNOTUMHSD11B1HSD11B2NPC1
SCHEMBL24988603 0.86 TSHR (0.45) TSHRNOTUMNPC1RAB9ALMNA
SCHEMBL25914443 0.85 MAPT (0.46) TSHRNOTUMHSD11B1HSD11B2NPC1
SCHEMBL25914371 0.84 TSHR (0.49) TSHRNOTUMNPC1RAB9ALMNA
SCHEMBL24987407 0.82 SPHK2 (0.47) TSHRNOTUMNPC1RAB9ACASP3
SCHEMBL24988115 0.82 SMN1; SMN2 (0.50) TSHRNPC1RAB9ALMNAALOX15
SCHEMBL24987312 0.81 TPH1 (0.44) HSD11B1HSD11B2LMNACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 — — US disclosed
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 — — US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 — — US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 — — US disclosed
EP-4122923-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-01-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A TSHR 2480/4885NOTUM 3472/4885HSD11B1 103/4885
US-20230265061-A1 OXADIAZOLE DERIVATIVE OXA1L, SCN1A, CACNA1A TSHR 2480/4885NOTUM 3472/4885HSD11B1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback